Shares of Inhibrx, Inc. (INBX) are rising more than 7% Tuesday morning after the company said Aventis Inc., a unit of Sanofi, has agreed to acquire all the assets and liabilities associated with INBRX-101, an augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency (AATD), for about $2.2 billion.
Prior to the closing of the transaction, Inhibrx will form a new publicly traded company, Inhibrx Biosciences, Inc. with its other assets and liabilities including INBRX-105, INBRX-106, INBRX-109.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.